StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note issued to investors on Monday. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Trading Down 1.5 %
PULM opened at $2.03 on Monday. The business’s 50 day moving average is $2.10 and its 200-day moving average is $1.98. The stock has a market cap of $7.41 million, a PE ratio of -0.84 and a beta of 0.99. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $2.75.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%. The business had revenue of $1.55 million for the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- How to Find Undervalued Stocks
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- How to Read Stock Charts for Beginners
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
